Healio

‘Pleasantly surprised’: Subcutaneous infliximab effective, regardless of Crohn’s location

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...
Seeking Alpha

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and ...

Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing ...
The New England Journal of Medicine

Resection of the Right Colon and Anastomosis of the Ileum to the Transverse Colon after the Mikulicz Plan

Read at the annual meeting of the New England Surgical Society, Portland, Maine, September 11, 1931.
Medscape

Ileal Resection Tied to Higher CRC Risk in Crohn's Disease

Patients with Crohn's disease who undergo terminal ileum resection have a significantly higher risk of developing colorectal cancer (CRC) and colorectal polyps than those who do not undergo resection.